Prof. Bronkhorstlaan 10-92
25 articles with InteRNA Technologies
InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy – Nucleic Acids and Oncotarget
Results further support the potential of lead candidate, INT-1B3, as novel option for therapeutic intervention in oncology
InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced that it was awarded a Clinical Innovation Credit of € 2.7 Million from the Dutch government.
Biopharma and life sciences companies from around the globe provide updates on their pipelines and businesses.
InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
InteRNA Technologies announced that the first patient has been dosed in the first cohort of its first-in-human Phase I study with the Company’s lead microRNA candidate, INT-1B3.
Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
First-in-human trial will test the safety, pharmacokinetics and preliminary efficacy of microRNA therapeutic candidate INT-1B3
5/16/2019Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more.
InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy
InteRNA Technologies announced today the recent publication of data from a collaboration with University Medical Center (UMC) Utrecht in Journal of Neuroscience showing that the downregulation of miR-135a levels can reduce seizure activity after the onset of spontaneous recurrent seizures (SRS) in chronic-stage Mesial Temporal Lobe Epilepsy (mTLE) in mouse models
3/29/2019Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.
InteRNA Technologies announced today the appointment of Andrea van Elsas, Ph.D., as a new member of the Company’s Scientific Advisory Board (SAB).
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting
Two poster presentations highlight INT-1B3’s immune-system activation and CD8+ T cell-driven anti-tumor response in addition to its distinct MoA, targeting multiple hallmarks of cancer.
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
INT-1B3 targets multiple hallmarks of cancer as a single agent resulting in immune-system activation, tumor regression and pronounced long term immunity
InteRNA Technologies Secures Final Extension Series A Financing And Strengthens Its Supervisory Board
InteRNA Technologies, UCB, Inc. And University of Bonn To Collaborate On The Role Of MicroRNAs In Neurodegenerative Disease
MiRacle Consortium Led by InteRNA Technologies and VU University Medical Center Along With Quiet Therapeutics Receives a €1.2 Million FP7 Grant From the European Union
InteRNA Technologies Secures Additional Equity Financing to Progress Lead Program for Melanoma Treatment
InteRNA Technologies Receives Notice of Allowance for miRNA Sequences of Its Lead Pre-Clinical Product
Silence Therapeutics plc and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics